Sarepta Therapeutics (SRPT) Change in Accured Expenses (2010 - 2026)

Sarepta Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 110.88% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was $69.2 million, a 70.58% decrease from a year earlier, with the FY2025 full-year figure at $104.3 million, down 5.77% from the prior year.
• Change in Accured Expenses eased to -$3.4 million in Q1 2026 per SRPT's latest filing, from $249.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $249.6 million in Q4 2025 and bottomed at -$103.2 million in Q3 2025.
• The 5-year median for Change in Accured Expenses is $1.7 million (2024), against an average of $18.2 million.
• Across the five-year window, Change in Accured Expenses surged 396.97% in 2024 and tumbled 6223.03% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $12.9 million in 2022, then jumped by 374.36% to $61.1 million in 2023, then jumped by 103.34% to $124.2 million in 2024, then surged by 100.96% to $249.6 million in 2025, then slumped by 101.38% to -$3.4 million in 2026.
• Per Business Quant, the three latest SRPT Change in Accured Expenses figures stand at -$3.4 million (Q1 2026), $249.6 million (Q4 2025), and -$103.2 million (Q3 2025).